MarketLens
Sign Up

Biotech IPOs in 2026: A New Wave

3 months ago
SHARE THIS ON:

Biotech IPOs in 2026: A New Wave

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Small-cap biotech stocks are rallying as macro and policy headwinds ease, with FDA stabilization and a resurgence in M&A and IPO activity restoring capital flows and investor confidence.
News2 weeks ago

Private-Equity Firms Eager for Exits Pounce on Hot IPO Market

Private-equity firms are accelerating IPOs as sluggish M&A limits exit options, with more companies going public to capitalize on a hot market.
News1 months ago

Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development

Scribe Therapeutics launched an IPO to fund CRISPR pipeline development. The Phase 1 biopharma's lead candidate, STX-1150, showed >50% LDL-C reduction in nonhuman primates, with first human data expec...
News1 months ago

U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

U.S. biotechs are tightening controls on proprietary data and processes to slow China's fast-follower drug development, shifting competitive strategy.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

Amazon's Toaster-Shaped Robotaxis Are Hitting the Road

Stock News2 hours ago

Tesla Maintained Its Majority of the U.S. EV Market in Q2, but That's Not All You Need to Know

Stock News3 hours ago

David Wagner on MSFT Moat Adding AI Momentum, Azure Backing CapEx Story

Stock News5 hours ago

2 Energy Stocks Riding the Data Center Power Crunch

Stock News8 hours ago

This is One of the Cheapest Magnificent Seven Stocks Right Now